News und Analysen
Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS AND ANNOUNCES ITS CASH POSITION AS OF 31 DECEMBER 2020
IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug
GenSight Biologics Announces its 2021 Financial Calendar
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
VALBIOTIS kündigt Teilnahme an der 39. jährlichen J.P. Morgan Healthcare Conference und der H.C. Wainwright BioConnect vom 11. bis 14. Januar 2021 im virtuellen Format an
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
VALBIOTIS Announces Its Participation in the 39th J.P. Morgan Healthcare Annual Conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in Virtual Format
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating
Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
Lyon, December 28, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP ANNOUNCE THE CREATION AND FUNDING OF NEW JOINT PUBLIC/PRIVATE LABORATORY "NEUROIMAGING FOR DRUG DISCOVERY" (NI2D)
The laboratory obtained funding of €350,000 from the French National Research Agency (ANR).
Lyon, 18 December 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of
Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the "Company" or "GenSight"), a biopharma company focused on developing and
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS : THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUES A FAVORABLE OPINION ON THE PRECLINICAL DEVELOPMENT PLAN SUBMITTED BY THERANEXUS AND BBDF
Lyon, 19 November 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF) announced securement of the
THERANEXUS : PRESENTATION OF THE RESULTS OF THE PHASE IB CLINICAL STUDY OF THN201 FOR ALZHEIMER'S DISEASE AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
The conference will take place remotely from 4 to 7 November 2020.
Lyon, 4 November 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer
GenSight Biologics Reports Validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Sensorion Announces Attendance and a Presentation at Upcoming Conferences
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS präsentiert erste Marktdaten zur unbehandelten LDL-Hypercholesterinämie für TOTUM-070 und gibt Start der klinischen Phase-II-Studie HEART bekannt
Pflichtmitteilung:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating
Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Obtains €3 Million Loans, Including €2 Million Guaranteed by the French Government (PGE) and €1 Million as RDI Loan Through Bpifrance
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS in den EnterNext© PEA-PME 150 Index der Euronext Paris aufgenommen
VALBIOTIS (Paris: ALVAL) (Euronext: ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechselkrankheiten
VALBIOTIS Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris
Regulatory News:
VALBIOTIS (Paris:ALVAL) (Euronext: ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it
ALPHA MOS : Sweet Ventures invests in BOYDSense
PRESS RELEASE
Sweet Ventures invests in BOYDSense to bring non-invasive glucose monitoring using breath analysis to people with diabetes
Toulouse (France) and Vienna (Austria), October 2nd